Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris

Caitlin M Brumfiel,1 Meera H Patel,2 Katheryn A Bell,1 Michael A Cardis3 1Georgetown University School of Medicine, Washington, DC, USA; 2Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA; 3MedStar Washington Hospital Center/Georgetown University Hospital Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Brumfiel CM, Patel MH, Bell KA, Cardis MA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	acne vulgaris trifarotene retinoid randomized controlled trials Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bd8dd91d550b4332b10e32eca89c0549
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd8dd91d550b4332b10e32eca89c0549
record_format	dspace
spelling	oai:doaj.org-article:bd8dd91d550b4332b10e32eca89c05492021-12-02T18:07:06ZAssessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris1178-203Xhttps://doaj.org/article/bd8dd91d550b4332b10e32eca89c05492021-07-01T00:00:00Zhttps://www.dovepress.com/assessing-the-safety-and-efficacy-of-trifarotene-in-the-treatment-of-a-peer-reviewed-fulltext-article-TCRMhttps://doaj.org/toc/1178-203XCaitlin M Brumfiel,1 Meera H Patel,2 Katheryn A Bell,1 Michael A Cardis3 1Georgetown University School of Medicine, Washington, DC, USA; 2Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA; 3MedStar Washington Hospital Center/Georgetown University Hospital Department of Dermatology, Washington, DC, USACorrespondence: Caitlin M BrumfielGeorgetown University School of Medicine, 3900 Reservoir Road, Washington, DC, 20007, USATel +1 513-260-3948Email cmb373@georgetown.eduAbstract: Acne vulgaris is a common skin condition of the face and trunk that negatively impacts quality of life. Trifarotene is a new first-in-class fourth-generation topical retinoid that has been uniquely studied in the treatment of both facial and truncal acne. Through selective agonism of retinoic acid receptor (RAR)-gamma, the most predominant RAR isotype in the epidermis, trifarotene exerts more targeted, skin-specific effects than earlier generation retinoids. This narrative review summarizes all currently available literature regarding the use of trifarotene in acne vulgaris. We focus on efficacy, safety, and tolerability data and highlight quality of life outcomes and patient-reported satisfaction. Future clinical trials and the clinical applicability of this novel medication in the treatment of acne are also discussed.Keywords: acne vulgaris, trifarotene, retinoid, randomized controlled trialsBrumfiel CMPatel MHBell KACardis MADove Medical Pressarticleacne vulgaristrifaroteneretinoidrandomized controlled trialsTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 755-763 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	acne vulgaris trifarotene retinoid randomized controlled trials Therapeutics. Pharmacology RM1-950
spellingShingle	acne vulgaris trifarotene retinoid randomized controlled trials Therapeutics. Pharmacology RM1-950 Brumfiel CM Patel MH Bell KA Cardis MA Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
description	Caitlin M Brumfiel,1 Meera H Patel,2 Katheryn A Bell,1 Michael A Cardis3 1Georgetown University School of Medicine, Washington, DC, USA; 2Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, AZ, USA; 3MedStar Washington Hospital Center/Georgetown University Hospital Department of Dermatology, Washington, DC, USACorrespondence: Caitlin M BrumfielGeorgetown University School of Medicine, 3900 Reservoir Road, Washington, DC, 20007, USATel +1 513-260-3948Email cmb373@georgetown.eduAbstract: Acne vulgaris is a common skin condition of the face and trunk that negatively impacts quality of life. Trifarotene is a new first-in-class fourth-generation topical retinoid that has been uniquely studied in the treatment of both facial and truncal acne. Through selective agonism of retinoic acid receptor (RAR)-gamma, the most predominant RAR isotype in the epidermis, trifarotene exerts more targeted, skin-specific effects than earlier generation retinoids. This narrative review summarizes all currently available literature regarding the use of trifarotene in acne vulgaris. We focus on efficacy, safety, and tolerability data and highlight quality of life outcomes and patient-reported satisfaction. Future clinical trials and the clinical applicability of this novel medication in the treatment of acne are also discussed.Keywords: acne vulgaris, trifarotene, retinoid, randomized controlled trials
format	article
author	Brumfiel CM Patel MH Bell KA Cardis MA
author_facet	Brumfiel CM Patel MH Bell KA Cardis MA
author_sort	Brumfiel CM
title	Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
title_short	Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
title_full	Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
title_fullStr	Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
title_full_unstemmed	Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris
title_sort	assessing the safety and efficacy of trifarotene in the treatment of acne vulgaris
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/bd8dd91d550b4332b10e32eca89c0549
work_keys_str_mv	AT brumfielcm assessingthesafetyandefficacyoftrifaroteneinthetreatmentofacnevulgaris AT patelmh assessingthesafetyandefficacyoftrifaroteneinthetreatmentofacnevulgaris AT bellka assessingthesafetyandefficacyoftrifaroteneinthetreatmentofacnevulgaris AT cardisma assessingthesafetyandefficacyoftrifaroteneinthetreatmentofacnevulgaris
_version_	1718378653615652864

Assessing the Safety and Efficacy of Trifarotene in the Treatment of Acne Vulgaris

Ejemplares similares